Analysts Conflicted on These Healthcare Names: ImmunoGen (NASDAQ: IMGN) and Agios Pharma (NASDAQ: AGIO)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on ImmunoGen (NASDAQ: IMGN) and Agios Pharma (NASDAQ: AGIO).

ImmunoGen (NASDAQ: IMGN)

Cowen & Co. analyst Boris Peaker assigned a Hold rating to ImmunoGen (NASDAQ: IMGN) today. The company’s shares opened today at $10.75.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 18.2% and a 53.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

ImmunoGen has an analyst consensus of Moderate Buy, with a price target consensus of $14.80.

See today’s analyst top recommended stocks >>

Agios Pharma (NASDAQ: AGIO)

Canaccord Genuity analyst John Newman maintained a Buy rating on Agios Pharma (NASDAQ: AGIO) today and set a price target of $90. The company’s shares opened today at $86.47, close to its 52-week high of $89.33.

According to TipRanks.com, Newman is a 5-star analyst with an average return of 18.7% and a 48.2% success rate. Newman covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Synergy Pharmaceuticals Inc, and Aileron Therapeutics Inc.

Currently, the analyst consensus on Agios Pharma is Strong Buy and the average price target is $100, representing a 15.6% upside.

In a report issued on May 6, Cowen & Co. also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.